Recent Publications

1. Shirasu, N. and Kuroki, Ma.: Simultaneous genotyping of single nucleotide polymorphisms in alcoholism-related genes using duplex and triplex allele-specific PCR with two-step thermal cycles. Anal. Sci., 30(11): 1093-1096, 2014.
2. Nam, S. O., Yotsumoto, F., Miyata, K., Suzaki, Y., Yagi, H., Odawara, T., Manabe, S., Ishikawa, T., Kuroki, Ma., Mekada, E. and Miyamoto, S.: Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy. Anticancer Res., 34(8): 4615-4620, 2014.
3. Kuroki, Ma. and Shirasu, N.: Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens. Anticancer Res., 34(8): 4481-4488, 2014.
4. Napathorn S. C., Kuroki, Mo. and Kuroki, Ma.: High expression of fusion proteins consisting of a single-chain variable fragment antibody against a tumor-associated antigen and interleukin-2 in Escherichia coli. Anticancer Res., 34(8): 3937-3946, 2014.
5. Anuleejun, S., Palaga, T., Katakura, Y., Kuroki, Mo., Kuroki, Ma. and Napathorn S. C.: Optimal production of a fusion protein consisting of a single-chain variable fragment antibody against a tumor-associated antigen and interleukin-2 in fed-batch culture of Pichia pastoris. Anticancer Res., 34(8): 3925-3935, 2014.
6. Shirasu, N., Yamada, H., Shibaguchi, H., Kuroki, Mo. and Kuroki, Ma.: Potent and specific antitumor effect of CEA-targeted photoimmunotherapy. Int. J. Cancer, 135 (11): 2697-2710, 2014.
7. Miyata, K., Yotsumoto, F., Nam, S. O., Odawara, T., Manabe, S., Ishikawa, T., Itamochi, T., Kigawa, J., Takada, S., Asahara, H., Kuroki, Ma. and Miyamoto, S.: Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma. Cancer Medicine, 3 (5): 1159-1169, 2014.
8. Yamaguchi, S., Zhang, B., Tomonaga, T., Seino, U., Kanagawa, A., Segawa, M., Nagasaka, H., Suzuki, A., Miida, T., Yamada, S., Sasaguri, Y., Doi, T., Saku, K., Okazaki, M., Tochino, Y. and Hirano, K.: Selective evaluation of high density lipoprotein from mouse small intestine by an in situ perfusion technique. J. Lipid Res., 55(5): 905-918, 2014.
9. Ishii, A., Kanaumi, T., Sohda, M., Misumi, Y., Zhang, B., Kakinuma, N,. Haga, Y., Watanabe, K., Takeda, S., Okada, M., Ueno, S., Kaneko, S., Takashima, S. and Hirose, S.: Association of nonsense mutation in GABRG2 with abnormal trafficking of GABAA receptors in severe epilepsy. Epilepsy Res., 108(3): 420-432, 2014.
10. Sasaki, M., Ishii, A., Saito, Y., Morisada, N., Iijima, K., Takada, S., Araki, A., Tanabe, Y., Arai, H., Yamashita, S., Ohashi, T., Oda, Y., Ichiseki, H., Hirabayashi, S., Yasuhara, A., Kawawaki, H., Kimura, S., Shimono, M., Narumiya, S., Suzuki, M., Yoshida, T., Oyazato, Y., Tsuneishi, S., Ozasa, S., Yokochi, K., Dejima, S., Akiyama, T., Kishi, N., Kira, R., Ikeda, T., Oguni, H., Zhang, B., Tsuji, S. and Hirose, S.: Genotype-phenotype correlations in alternating hemiplegia of childhood. Neurology, 82(6): 482-490, 2014.
11. Hanaoka, H., Kuroki, Ma., Yamaguchi, A., Achmad, A., Iida, Y., Higuchi, T., Oriuchi, N., Tsushima, Y. and Endo, K.: Fractionated radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody. Cancer Biother. Radiopharm., 29(2): 70-76, 2014.
12. Higurashi, N., Uchida, T., Lossin, C., Misumi, Y., Okada, Y., Akamatsu, W., Imaizumi, Y. Zhang, B., Nabeshima, K., Mori, M. X., Katsurabayashi, S., Shirasaka, Y., Okano, H. and Hirose, S.: A human Dravet syndrome model from patient induced pluripotent stem cells. Mol. Brain, 6(1): 19, 2013.
13. Inoue, T., Ihara, Y., Tomonoh, Y., Nakamura, N., Ninomiya, S., Fujita, T., Ideguchi, H., Yasumoto, S., Zhang, B. and Hirose, S.: Early onset and focal spike discharges as indicators of poor prognosis for myoclonic-astatic epilepsy. Brain Dev., doi: 10.1016/j.braindev.2013.08.009, 2013.
14. Uehara, Y., Ando, S., Yahiro, E., Oniki, K., Ayaori, M., Abe, S., Kawachi, E., Zhang, B., Shioi, S., Tanigawa, H., Imaizumi, S., Miura, S. and Saku, K.: FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in ApoE-deficient mice. J. Am. Heart Assoc., 2(3): e000048, 2013.
15. Kumagai, N., Miura, S., Zhang, B., Noda, K., Saku, K. and Zenith Trial Investigators.: Effects of ezetimibe on hypercholesterolemia in the lipid profile in patients with metabolic syndrome: Zenith Trial. IJC Metablic & Endocrine, 1(1): 7-12, 2013.
16. Zhang, B. Kawachi, E., Miura, S., Uehara, Y., Matsunaga, A., Kuroki, Ma. and Saku, K.: Therapeutic approaches to the regulation of HDL metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise. Circ. J., 77(11): 2651-2663, 2013.
17. Nam, S O., Yotsumoto, F., Miyata, K., Shirasu, N., Miyamoto, S and Kuroki, Ma.: Possible therapeutic targets among the molecules involved in the warburg effect in tumor cells. Anticancer Res., 33 (7): 2855-2860, 2013.
18. Shirasu, N., Nam, S O. and Kuroki, Ma.: Tumor-targeted photodynamic therapy. Anticancer Res., 33 (7): 2823-2831, 2013.
19. Yotsumoto, F., Tokunaga, E., Oki, E., Maehara, Y., Yamada, H., Nakajima, K., Nam, S. O., Miyata, K., Koyanagi, M., Doi, K., Shirasawa, S., Kuroki, Ma. and Miyamoto, S.: Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer. Mol Cancer Res. 11(5): 506-517, 2013.
20. Ishitsuka, K., Kunami, N., Katsuya, H., Nogami, R., Ishikawa, C., Yotsumoto, F., Tanji, H., Mori, N., Takeshita, M., Miyamoto, S. and Tamura, K.: Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737., Cancer Lett., 317(2): 218-225, 2012.
21. Nojiri, T., Yoshizato, T., Fukami, T., Obama, H., Yagi, H., Yotsumoto, F. and Miyamoto, S.: Clinical significance of amphiregulin and epidermal growth factor in colostrum., Arch Gynecol Obstet., 286(3): 643-647, 2012.
22. Kasai, N., Kobayashi, K., Shioya, S., Yoshikawa, Y., Yotsumoto, F., Miyamoto, S., Mekada, E. and Enokizono, J.: Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer., Am J Transl Res., 4(4): 415-421, 2012.
23. Morii, J., Miura, S., Shiga, Y., Sugihara, M., Arimura, T., Sako, H., Zhang, B., Uehara, Y. and Saku, K.: Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study). Clin. Exp. Hypertens, 34(5): 342-349, 2012.
24. Noda, K., Zhang, B., Iwata, A., Nishikawa, H., Ogawa, M., Nomiyama, T., Miura, S., Sako, H., Matsuo, K., Yahiro, E., Yanas, T., Saku, K., on behalf of the STYLIST Study Investigators.: Lifestyle changes through the use of delivered meals and dietary counseling in a single-blind study. The STYLIST study. Circ. J., 76(6): 1335-1344, 2012.
25. Uchida, H., Marzulli, M., Nakano, K., Goins, W. F., Chan, J., Hong, C. S., Mazzacurati, L., Yoo, J. Y., Haseley, A., Nakashima, H., Baek, H., Kwon, H., Kumagai, I., Kuroki, Ma., Kaur, B., Chiocca, E. A., Grandi, P., Cohen, J. B. and Glorioso, J. C.: Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol. Ther., 21(3): 561-569, 2012.
26. Zhang, B., Kawachi, E., Matsunaga, A., Imaizumi, S., Noda, K., Uehara, Y., Miura, S., Yoshinaga, K., Kuroki, Ma. and Saku, K.: Reactivity of direct assays for Low-Density Lipoprotein (LDL) cholesterol toward charge-modified LDL in hypercholesterolemia. Circ. J., 76(9): 2241-2248, 2012.
27. Tsuru, H., Shibaguchi, H., Kuroki, Mo., Yamashita, Y. and Kuroki, Ma.: Tumor growth inhibition by sonodynamic therapy using a novel sonosensitizer. Free Radic. Biol. Med., 53 (3): 464-472, 2012.
28. Shirasu, N. and Kuroki, Ma.: Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes. Anticancer Res., 32 (6): 2377-2383, 2012.
29. Miyata, K., Yotsumoto, F., Nam, S O., Kuroki, Ma. and Miyamoto, S.: Regulatory Mechanisms of the HB-EGF Autocrine Loop in Inflammation, Homeostasis, Development and Cancer. Anticancer Res., 32 (6): 2347-2352, 2012.
30. Yoshida, Y., Tsunoda, T., Doi, K., Fujimoto, T., Tanaka, Y., Ota, T., Ogawa, M., Matsuzaki, H., Kuroki, Ma., Iwasaki, A. and Shirasawa, S.: ALPK2 is Crucial for Luminal Apoptosis and DNA Repair-related Gene Expression in a Three-dimensional Colonic-crypt Model. Anticancer Res., 32 (6): 2301-2308, 2012.
31. Ota, T., Doi, K., Fujimoto, T., Tanaka, Y., Ogawa, M., Matsuzaki, H., Kuroki, Ma., Miyamoto, S., Shirasawa, S. and Tsunoda, T.: KRAS Up-regulates the Expression of miR-181a, miR-200c and miR-210 in a Three-dimensional-specific Manner in DLD-1 Colorectal Cancer Cells. Anticancer Res., 32 (6): 2271-2275, 2012.
32. Kuroki, Ma., Miyamoto, S., Morisaki, T., Yotsumoto, F., Shirasu, N., Taniguchi, Y. and Soma, G.： Biological response modifiers used in cancer biotherapy. Anticancer Res., 32 (6): 2229-2233, 2012.
33. Shibaguchi, H., Tsuru H., Kuroki, Mo. and Kuroki, Ma.: Enhancement of the antitumor effect on combination therapy of an anticancer drug and its antibody against carcinoembryonic antigen. Chemotherapy, 58(2):110-117, 2012.
34. Shirasu, N., Yamada, H., Shibaguchi, H., Kuroki, Mo. and Kuroki, Ma.: Molecular characterization of a fully human chimeric T cell antigen receptor for tumor-associated antigen EpCAM. J. Biomed. Biotechnol., doi:10.1155/2012/853879, 2012.
35. Tsunoda, T., Ota, T., Fujimoto, T., Doi, K., Tanaka, Y., Yoshida, Y., Ogawa, M., Matsuzaki, H., Hamabashiri, M., Tyson, D. R., Kuroki, Ma., Miyamoto, S. and Shirasawa, S.: Inhibition of Phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model. Mol. Cancer, 11(1): 46, 2012.
36. Doi, K., Fujimoto, T., Okamura, T., Ogawa, M., Tanaka, Y., Mototani, Y., Goto, M., Ota, T., Matsuzaki, H., Kuroki, Ma., Tsunoda, T., Sasazuki, T. and Shirasawa, S.: ZFAT plays critical roles in peripheral T cell homeostasis and its T cell receptor-mediated response. Biochem. Biophys. Res. Commun., doi: 10.1016/j.bbrc.2012.07.065, 2012.
37. Miyamoto, S., Iwamoto, R., Furuya, A., Takahashi, K., Sasaki, Y., Ando, H., Yotsumoto, F., Yoneda, T., Hamaoka, M., Yagi, H., Murakami, T., Hori, S., Shitara, K. and Mekada, E.: A novel anti-human HB-EGF monoclonal antibody with multiple anti-tumor mechanisms against ovarian cancer cells. Clin. Cancer Res., 17(21): 6733-6741, 2011.
38. Koshikawa, N., Mizushima, H., Minegishi, T., Eguchi, F., Yotsumoto, F., Nabeshima, K., Miyamoto, S., Mekada, E. and Seiki, M.: Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells. Cancer Sci., 102(1): 111-116, 2011.
39. Arishima, H., Matsunaga, A., Uehara, Y., Niimura, H., Zhang, B., Ohwaki, K., Hayashida, K., Yoshimizu, K. and Saku, K.: Statins induce the gene expression of apolipoprotein A5 in HepG2 cells. Med. Bull. Fukuoka Univ., 38(4): 161-169, 2011.
40. Mito, T., Miura, S., Iwata, A., Morii, J., Sugihara, M., Ike, A., Mori, K., Kawamura, A., Nishikawa, H., Zhang, B. and Saku, K.: Determination of the cut-off plasma adiponectin level assosiated with a lower risk of restenosis in patients with stable angina. Coronary Artery Dis., 22(7): 451-457, 2011.
41. Iwata, A., Miura, S., Zhang, B., Imaizumi, S., Uehara, Y., Shiomi, M. and Saku K.: Antiatherogenic effects of newly-developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis, 218(2): 300-307, 2011.
42. Takahira, M., Noda, K., Fukushima, M., Zhang, B., Mitsutake, R., Uehara, Y., Ogawa, M., Kakuma, T. and Saku, K.: Randomized double-blind controlled comparative trial of food containing soy protein vs. milk protein in visceral fat obesity. -FLAVO Study-. Circ. J., 75(9): 2235-2243, 2011.
43. Kuwano, T., Miura, S., Shirai, K., Ike, A., Mori, K., Shimizu, T., Zhang, B., Iwata, A., Nishikawa, H., Kawamura, A. and Saku, K.: Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: a new look at an old molecule. J. Atheroscler. Thromb., 18(7): 574-583, 2011.
44. Saku, K., Zhang, B. and Noda, K.: Randomized head-to-head comparison of pitavastatin, atorvastatin, and, rosuvastatin for safety and efficacy (quantity and quality of LDL) - the PATROL trial -. Circ. J., 75(6): 1493-1505, 2011.
45. Ike, A., Nishikawa, H., Shirai, K., Mori, K., Kuwano, T., Fukuda, Y., Takamiya, Y., Yanagi, D., Kubota, K., Tsuchiya, Y., Zhang, B., Miura, S. and Saku, K.: Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention - from the FU-registry -. Circ. J., 75(4): 791-799, 2011.
46. Takamiya, Y., Miura, S., Tsuchiya, Y., Fukuda, Y., Zhang, B., Kuwano, T., Ike, A., Yanagi, D., Kubota, K., Mori, K., Iwata, A., Nishikawa, H., Kawamura, A., Miller, N., Matsuo, K., Shirai, K. and Saku, K.: Angiographic late lumen loss at the site of overlap of multiple CypherTM sirolimus-eluting stents: ALSOCE study. J. Cardiol., 57(2): 187-193, 2011.
47. Fujimoto, T., Machida, T., Tsunoda, T., Doi, K., Ota, T., Kuroki, Ma. and Shirasawa, S.: Determination of the critical region of KRAS-induced actin-interacting protein for the interaction with inositol 1,4,5-trisphosphate receptor. Biochem. Biophys. Res. Commun., 408 (2): 282-286, 2011.
48. Fujimoto, T., Machida, T., Tsunoda, T., Doi, K., Ota, T., Kuroki, Ma. and Shirasawa, S.: KRAS-induced actin-interacting protein regulates inositol 1,4,5-trisphosphate-receptor-mediated calcium release. Biochem. Biophys. Res. Commun., 408 (2): 214-217, 2011.
49. Fujimoto, T., Machida, T., Tanaka, Y., Tsunoda, T., Doi, K., Ota, T., Okamura, T., Kuroki, Ma. and Shirasawa, S.: KRAS-induced actin-interacting protein is required for the proper localization of inositol 1,4,5-trisphosphate receptor in the epithelial cells. Biochem. Biophys. Res. Commun., 407 (2): 438-443, 2011.
50. Shirasu, N., Houtman, J.C., Yamaguchi, H., Barda-Saad, M., Appella, E., Schuck, P., Samelson, L.E.: Site-specific fluorescent labeling of VAV by sortase-mediated transpeptidation. Peptide Science 2010 (2011), pp.184, 2011.
51. Tsujioka, H., Yotsumoto, F., Hikita, S., Ueda, T., Kuroki, Ma. and Miyamoto, S.: Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Curr. Opin. Obstet. Gynecol., 23: 24-30, 2011.
52. Nakata, K., Taniguchi, Y., Yoshioka, N., Yoshida, A., Inagawa, H., Nakamoto, T., Yoshimura, H., Miyake, S., Kohchi, C., Kuroki, Ma. and Soma, G.: A mixture of Salacia oblonga extract and IP-PA1 reduces fasting plasma glucose (FPG) and low-density lipoprotein (LDL) cholesterol levels. Nutr Res Pract., 5 (5): 435-442, 2011.
53. Choijamts, B., Jimi, S., Kondo, T., Naganuma, Y., Matsumoto, T., Kuroki, Ma., Iwasaki, H. and Emoto, M.: CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Mullerian tumor). Stem Cells., 29: 1485-1495, 2011.
54. Hikita, S., Yotsumoto, F., Fumaki, T, Horiuchi, S., Sanui, A., Miyata, K., Nam, S., Tsujioka, H., Ueda, T., Shirota, K., Yoshizato, T., Maeda, K., Ishikawa, T., Okuno, Y., Kuroki, Ma., Mekada, E. and Miyamoto, S.: Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA. Anticancer Res., 31 (7): 2553-2560, 2011.
55. Yoshida, Y., Tsunoda, T., Doi, K., Tanaka, Y., Fujimoto, T., Machida, T., Ota, T., Koyanagi, M., Takashima, Y., Sasazuki, T., Kuroki, Ma., Iwasaki, A. and Shirasawa, S.: KRAS-mediated upregulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res., 31 (7): 2535-2540, 2011.
56. Ohmura, T., Fukushima, T., Shibaguchi, H., Yoshizawa, S., Inoue, T., Kuroki, Ma., Sasaki, K. and Umemura, S.: Sonodynamic therapy with 5-aminolevulinic acid and focused ultrasound for deep-seated intracranial glioma in rat. Anticancer Res., 31 (7): 2527-2534, 2011.
57. Higashi, D., Futami, K., Ishibashi, Y., Egawa, Y., Maekawa, T., Matsui, T., Iwashita, A. and Kuroki, Ma.: Clinical course of colorectal cancer in patients with ulcerative colitis. Anticancer Res., 31 (7): 2499-2504, 2011.
58. Kunami, N., Yotsumoto, F., Ishitsuka, K., Fukami, T., Odawara, T., Manabe, S., Ishikawa, T., Tamura, K., Kuroki, Ma. and Miyamoto, S.: Anti-tumor effects of CRM197, a specific inhibitor for HB-EGF, in T-cell acute lymphoblastic leukemia. Anticancer Res., 31 (7): 2483-2488, 2011.
59. Tsujioka, H., Fukami, T., Yotsumoto, F., Ueda, T., Hikita, S., Takahashi, Y., Kondo, H., Kuroki, Ma. and Miyamoto, S.: A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer. Anticancer Res., 31 (7): 2461-2466, 2011.
60. Tsunoda, T., Takashima, Y., Yoshida, Y., Doi, K., Tanaka, Y., Fujimoto, T., Ota, T., Koyanagi, M., Kuroki, Ma., Sasazuki, T. and Shirasawa, S.: Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells. Anticancer Res., 31 (7): 2453-2460, 2011.
61. Shibaguchi, H., Tsuru, H., Kuroki, Mo. and Kuroki, Ma.: Sonodynamic cancer therapy: a non-invasive and repeatable approach using low-intensity ultrasound with a sonosensitizer. Anticancer Res., 31 (7): 2425-2430, 2011.
62. Baek, H., Uchida, H., Jun, K., Kim, J. H., Kuroki, Ma., Cohen, J. B., Glorioso J. C. and Kwon, H.: Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.Molecular Therapy 19, 507-514, 2011.
63. Doi, K., Fujimoto, T., Koyanagi, M., Tsunoda, T., Tanaka, Y., Yoshida, Y., Takashima, Y., Kuroki, M., Sasazuki, T. and Shirasawa, S.: ZEAT is a critical molecule for cell survival in mouse embryonic fibroblasts. Cell Mol. Biol. Lett.,16(1): 89-100, 2011.
64. Yoshida, Y., Tsunoda, T., Takashima, Y., Fujimoto, T., Doi, K., Sasazuki, T., Kuroki, Ma., Iwasaki, A. and Shirasawa S. ZFAT is essential for endothelial cell assembly and the branch point formation of capillary-like structures in an angiogenesis model. Cell Mol. Biol. Lett., 15(4): 541-550, 2010.
65. Yotsumoto, F., Fukami, T., Yagi, H., Funakosi, A., Yoshizato, T., Kuroki, Ma. and Miyamoto, S.: Amphiregulin regulates the activation of ERK and Akt through EGFR and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci., 101 (11): 2351-2360, 2010.
66. Sanui, A., Yotsumoto, F., Tsujioka, H., Fukami, T., Horiuchi, S., Shirota, K., Yoshizato, T., Kawarabayashi, T., Kuroki, Ma. and Miyamoto, S.: HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Res., 30 (8), 3143-3149, 2010.
67. Tsujioka, H., Yotsumoto, F., Shirota, K., Horiuchi, S., Yoshizato, T., Kuroki, Ma. and Miyamoto, S.: Emerging strategies for ErbB ligand-based targeted therapy for cancer. Anticancer Res., 30 (8), 3107-3112, 2010.
68. Tsujioka, H., Hachisuga, T., Hikita, S., Ueda, T., Yotsumoto, F., Shirota, K., Yoshizato, T., Kawarabayashi, T., Kuroki, Ma. and Miyamoto, S.: Apotosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations. Anticancer Res, 30 (8): 3119-3123, 2010.
69. Yotsumoto, F., Oki, E., Tokunaga, E., Maehara, Y., Kuroki, Ma. and Miyamoto, S.: HB-EGF Orchestrates the Complex Signals Involved in Triple-negative and Trastuzumab-resistant Breast Cancer. Int. J. Cancer, 127 (11): 2707-2717, 2010.
70. Tsunoda, T., Takashima, Y., Tanaka, Y., Fujimoto, T., Doi, K., Hirose, Y., Koyanagi, M., Yoshida, Y., Okamura, T., Kuroki, Ma., Sasazuki, T. and Shirasawa, S.: Immune-related zinc finger gene ZFAT is an essential transcriptional regulator for hematopoietic differentiation in blood islands. Proc. Natl. Acad. Sci. USA., 107 (32): 14199-14204, 2010.
71. Shirasu N, Shibaguci H, Kuroki M, Yamada H, Kuroki Ma : Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer Res. 30 (7):2731-2738, 2010.
72. Barda-Saad M, Shirasu N, Pauker MH, Hassan N, Perl O, BalboA, Yamaguchi H, Houtman JC, Appella E, Schuck P, Samelson LE.: Cooperative interactions at the SLP-76 complex are critical for actin polymerization. EMBO J. 29 (14): 2315-28, 2010.
73. Tsunoda, T., Takashima, Y., Fujimoto, T., Koyanagi, M., Yoshida, Y., Doi, K., Tanaka, Y., Kuroki, Ma., Sasazuki, T. and Shirasawa, S.: Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. NeoPlasia, 12 (5): 397-404, 2010.
74. Mizoe, Y., Shioi, N., Terada, S., Uchida, Y., Kuroki, Ma. and Lee, S.: Characteristic difference of biological activity between Arg-containing and Lys-containing peptide. In: Peptide Science 2009. (K. Okamoto, ed.), The Japanese Peptide Society (Fukuoka), pp. 213-216, 2010.
75. Tanaka, T., Shibaguchi, H., Maekawa, S., Shimura, H., Tamura, K. and Kuroki, Ma.: Recent developments in cancer gene therapy with adenovirus vectors. Trends in Cancer Res., 5: 63-69, 2009.
76. Shibaguchi., H. Tanaka, T., Luo, N. and Kuroki, Ma.: Engineering T cells in cancer immunotherapy: strategy for gene construction and antitumor activity. Trends in Cancer Res., 5: 21-27, 2009.
77. Yanagisawa, J., Shiraishi, T., Iwasaki, A., Maekawa, S., Higuchi, T., Hiratuka, M., Tanaka, T., Shibaguchi, H., Kuroki, Ma. and Shirakusa, T.: PPARalpha ligand WY14643 reduced acute rejection after rat lung transplantation with the upregulation of IL-4, IL-10 and TGFbeta mRNA expression. J. Heart Lung Transpl., 28(11): 1172-9, 2009.
78. Yotsumoto, F., Sanui, A., Fukami, T., Shirota, K., Horiuchi, S., Tsujioka, H., Yoshizto, T., Kuroki, Ma. and Miyamoto, S.: Efficacy of ligand-based targeting for the EGF system in cancer. Anticancer Res., 29(11): 4879-4885, 2009.
79. Ikeda, T., Nakayama, Y., Hamada, Y., Takeshita, M., Iwasaki, H., Maeshiro, K., Yamashita, Y., Kuroki, Ma and Ikeda, S.: FU-MK-1 expression in human gallbladder carcinoma: An antigenic prediction marker for a better postsurgical prognosis. Am. J. Clin. Pathol., 132 (1): 111-117, 2009.
80. Inoue, Y., Miyamoto, S., Fukami, T., Shirota, K., Yotsumoto, F. and Kawarabayashi, T.: Amphiregulin is much more abundantly expressed than transforming growth factor-alpha and epidermal growth factor in human follicular fluid obtained from patients undergoing in vitro fertilization-embryo transfer. Fertility and Sterility, 91 (4): 1035-1041, 2009.
81. Fukami, T., Yoshizato, T., Miyamoto, S., Yagi, H., Yotsumoto, F., Nabeshima, K., Hachisuga, T., Kuroki, Ma. and Kawarabayashi, T.: Amphiregulin regulates the production of human chorionic gonadotropin in trophoblasts. Life Sci., 84 (23-24): 796-804, 2009.
82. Kuroki, Ma.: A solid-phase mutual inhibition assay with labeled antigen. In: Methods in Molecular Biology, Vol.524, Epitope Mapping Protocols (U. Reineke and M. Schutkowski, eds.), Humana Press, Totowa, NJ, pp. 59-66, 2009.
83. Miyamoto, S., Fukami, T., Yagi, H., Kuroki, Ma. and Yotsumoto, F.: Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. Anticancer Res., 29 (3): 823-830, 2009.
84. Huo, Q., Kinugasa, T., Wang, L., Huang, J., Zhao, J., Shibaguchi, H., Kuroki, Mo., Tanaka, T., Yamashita, Y., Nabeshima, K., Iwasaki, H. and Kuroki, Ma.: Claudin-1 protein is a major factor involved in the tumorigenesis of colorectal cancer. Anticancer Res., 29 (3):851-857, 2009.
85. Huang, J., Hunag, WX., Li, HY., Xia, ZH., Hu, CP., MA, YL., Chen, L., Yu, XY. and Kuroki, Ma.: Relationship between the I883M polymorphism of ATP-binding cassette transporter 1 gene and cardiovascular disease. Shandong Med. J., 49 (9): 3-5, 2009.
86. Yagi, H., Yotsumoto, F., Sonoda, K., Kuroki, Ma., Mekada, E. and Miyamoto, S.: Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int. J. Cancer, 124 (6): 1429-1439, 2009.
87. Huo, Q., Kinugasa, T. and Kuroki, Ma.: Construction of expression vectors of tight junction proteins claudin-1 and claudin-2. J. Guangxi Med. Univ., 25 (5):703-705, 2008.
88. Huo, Q., Kinugasa, T. and Kuroki, Ma.: Expression and distribution of tight junction proteins in colorectal cancer. Chin. J. Lab. Med., 31 (9): 997-1001, 2008.
89. Zhao, J., Kuroki, Mo., Shibaguchi, H., Wang, L., Takami, N., Tanaka, T., Kinugasa, T. and Kuroki, Ma.: Recombinant human monoclonal IgA antibody against CEA to recruit neutrophils to CEA-Expressing Cells. Oncol. Res., 17 (5): 217-222, 2008.
90. Yagi, H., Yotsumoto, F. and Miyamoto, S.: Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol. Cancer Ther., 7 (10): 3441-3451, 2008.
91. Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E.: Heparin-binding epidermal growth factor-like growth factor as a new target molecule for cancer therapy. Adv. Exp. Med. Biol., 622:281-95, 2008.
92. Maekawa, S., Iwasaki, A., Shirakusa, T., Kawakami, T., Yanagisawa, J., Tanaka, T., Shibaguchi, H., Kinugasa, T., Kuroki, Mo. and Kuroki, Ma.: Association between the expression of chemokinereceptors CCR7 and CXCR3, and lymph nodemetastatic potential in lung adenocarcinoma. Oncol. Rep., 19 (6): 1461-1468, 2008.
93. Uchida, H., Kuroki, Mo., Shitama, T., Hayashi, H. and Kuroki, Ma.: Activation of TGF-b1 through up-regulation of TSP-1 by retinoic acid in retinal pigment epithelial cells. Curr. Eye Res., 33 (2): 199-203, 2008.
94. Huo, Q., Kinugasa, T., Tanaka, T., Zhao, J. and Kuroki, Ma.: Analysis of the expression of tight junction-associated proteins in colorectal cancer. Mol. Tumor Marker Res., 23 (1): 27-28, 2008.
95. Uchino, J., Takayama, K., Harada-Ikegami, A., Sone, T., Harada, T., Curiel, D. T., Kuroki, Ma. and Nakanishi, Y.: Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan. Cancer Gene Ther., 15 (2): 94-100, 2008.
96. Sonoda, K., Miyamoto, S., Nakashima, M. and Wake, N.: Biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front. Biosci., 13: 1106-1116, 2008.
97. Yotsumoto, F., Yagi, H., Suzuki, O. S., Oki, E., Tsujioka, H., Hachisuga, T., Sonoda, K., Kawarabayashi, T., Mekada, E. and Miyamoto, S.: Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem. Biophys. Res. Commun., 365(3): 555-561, 2008.
98. Tanaka, T., Hamada, H., Kuroki, Mo., Kato, K., Zhao, J., Kinugasa, T., Shibaguchi, H. and Kuroki, Ma.: Application of antibody for targeting of cancer gene therapy. Current Trends in Immunology, 8 (1): 27-33, 2007.
99. Nakamura, K., Kato, K., Tanaka, T., Hamada, H..: Targeting vectors for cancer gene therapy. In 21st Century's Center of Excellence Program of Japanese Ministry of Education and Science, Gene therapy 2007 (Ochiai, T., Shimada, H. and Tagawa, M., ed.), 文部科学省　21世紀COEプログム　千葉大学プロジェクト「消化器扁平上皮癌の最先端多戦略治療拠点形成」, pp 86-94, 2007.
100. Sonoda, K., Miyamoto, S., Yamazaki, A., Kobayashi, H., Nakashima, M., Mekada, E. and Wake, N.: Biologic significance of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) as a pivotal regulator of tumor growth through angiogenesis in human uterine cancer. Cancer, 110(9):1979-1990, 2007.
101. Kageyama, T., Ohishi, M., Miyamoto, S., Mizushima, H., Iwamoto, R. and Mekada, E.: Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity. J. Biochem., 142 (1): 95-104, 2007.
102. Sonoda, K., Miyamoto, S., Yotsumoto, F., Yagi, H., Nakashima, M., Watanabe, T. and Nakano, H.: Clinical significance of RCAS1 as a biomarker of ovarian cancer. Oncol. Rep., 17 (3): 623-628, 2007.
103. Kuroki, Ma., Hachimine, K., Abe, H., Shibaguchi, H., Kuroki, Mo., Maekawa, S., Yanagisawa, J., Kinugasa, T., Tanaka, T. and Yamashita, Y.: Sonodynamic therapy of cancer using novel sonosensitizers. Anticancer Res., 27 (6): 3673-3678, 2007.
104. Tanaka, T., Kuroki, Mo., Hamada, H., Kato, K., Kinugasa, T., Shibaguchi, H., Zhao, J. and Kuroki, Ma.: Cancer-targeting gene therapy using tropism-modified adenovirus. Anticancer Res., 27 (6): 3679-3684, 2007.
105. Miyamoto, S., Yagi, H., Yotsumoto, F., Horiuchi, S., Yoshizato, T., Kawarabayashi, T., Kuroki, Ma. and Mekada, E.: New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule. Anticancer Res., 27 (6): 3713-3722, 2007.
106. Kinugasa, T., Huo, Q., Higashi, D., Shibaguchi, H., Kuroki, Mo., Tanaka, T., Futami, K., Yamashita, Y., Hachimine, K., Maekawa, S., Nabeshima, K., Iwasaki, H. and Kuroki, Ma.: Selective up-regulation of Claudin-1 and Claudin-2 in colorectal cancer. Anticancer Res., 27 (6): 3729-3734, 2007.
107. Maekawa, S., Iwasaki, A., Shirakusa, T., Enatsu, S., Kawakami, T., Kuroki, Mo. and Kuroki, Ma.: Correlation between lymph node metastasis and expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. Anticancer Res., 27 (6): 3735-3742, 2007.
108. Tanaka, T., Hamada, H., Kuroki, Mo., Kato, K., Kinugasa, T., Shibaguchi, H. and Kuroki, Ma.: Targeting strategies by coupling of adenovirus vector and antibody for cancer gene therapy. Recent Developments in Gene Therapy, 2007. (J. Xiang, ed.), Transworld Research Network, Kerala (India), pp. 319-326, 2007.
109. Hachimine, K., Shibaguchi, H., Kuroki, Mo., Yamada, H., Kinugasa, T., Nakae, Y., Asano, R., Sakata, I., Yamashita, Y., Shirakusa, T. and Kuroki, Ma.: Sonodynamic therapy of cancer using a novel porphyrin derivative, DCPH-P-Na(I), which is devoid of photosensitivitiy. Cancer Sci., 98 (6): 916-920, 2007.
110. Kinugasa, T., Kuroki, Mo., Toyohara, T., Morita, N., Kuromizu, J., Yamashita, Y., Shirakusa, T., Shibaguchi, H. and Kuroki, Ma.: Granulocyte and monocyte adsorption apheresis therapy for ulcerative colitis patients: a useful tool for surgical indication assessments. Med. Bull. Fukuoka Univ., 33 (4): 283-291, 2006.
111. Kuroki, Ma., Huang, J., Shibaguchi, H., Tanaka, T., Zhao, J., Luo, N., Hachimine, K., Kinugasa, T., Maekawa, S., Enatsu, S., Hamanaka, W., Fukami, T. and Kuroki, Mo.: Possible applications of antibodies or their genes in cancer therapy. Anticancer Res., 26 (6): 4019-4026, 2006.
112. Shibaguchi, H., Luo, N., Kuroki, Mo., Zhao, J., Huang, J., Hachimine, K., Kinugasa, T. and Kuroki, Ma.: A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer Res., 26 (6): 4067-4072, 2006.
113. Huang, J., Shibaguchi, H. and Kuroki, Ma.: Replacement of the constant region gene of a novel anti-CEA antibody and characterization of its biological activity. Chin. J. Cell. Mol. Immunol., 22 (5): 650-653, 2006.
114. EL-Meghawry EL-Kenawy, A., EL-Kott, A.F., Hamed, S.M., Kuroki, Ma.: Prognostic value of carcinoma-associated antigen MK-1 in urinary bladder carcinoma. Int. J. Biol. Markers, 21 (3): 170-174, 2006.
115. Sasaki, T., Ikeda, H., Sato, M., Ohkuri, T., Abe, H., Kuroki, Ma., Onodera, M., Miyamoto, M., Kondo, S. and Nishimura, T.: Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells. Cancer Sci., 97 (9): 920-927, 2006.
116. Enatsu, S., Iwasaki, A., Shirakusa, T., Hamasaki M., Nabeshima, K., Iwasaki, H., Maekawa, S., Kuroki, Mo. and Kuroki, Ma.: Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung. Eur. J. Cardiothorac. Surg., 29 (6): 891-895, 2006.
117. Tanaka, T., Huang, J., Hirai, S., Kuroki, Mo., Kuroki, Ma., Watanabe, N., Kato, K. and Hamada, H.: Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin. Cancer Res., 12 (12): 3803-3813, 2006.
118. Tokunaga, I., Lee S., Yamada, H., Kuroki, Mo. and Kuroki, Ma.: Effect of innovation of D-anino acids into novel anti-tumor peptide and protein on their conformation and cytotoxicities. Peptide Science 2005. (T. Wakamiya, ed.), The Japanese Peptide Society (Osaka), pp. 213-216, 2006.
119. Huang, J., Shibaguchi, H., Kuroki, Mo., Hirose, Y., Yamada, H., Zhao, J., Kinugasa, T. and Kuroki, Ma.: Subclass conversion from IgG4 to IgG1 of a novel human anti-CEA antibody for increasing its biological activity. Mol. Tumor Marker Res., 21(1): 53-54, 2006.
120. Huang, J., Shibaguchi, H., Zhao, J., Luo, N., Kuroki, Mo., Kinugasa, T., Hirose, Y., Yamada, H. and Kuroki, Ma.: IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity. Anticancer Res., 26 (2): 1057-1064, 2006.
121. Kuroki, Ma., Shibaguchi, H., Kuroki, Mo., Kinugasa, T., Hachimine, K., Enatsu, S., Maekawa, S., Huang, J. and Zhao, J.: Targeting of cancer gene therapy with antibodies or their genes against tumor-associated antigens. Gene Ther. Mol. Biol., 9 (A):107-112, 2005.
122. Higuchi, T., Shiraishi, T., Hirayama, S., Shibaguchi, H., Kuroki, Mo., Hiratsuka, M., Yamamoto, S., Iwasaki, A., Kuroki, Ma. and Shirakusa, T.: Prevention of acute lung allograft rejection in rat by the Janus kinase 3 inhibitor, tyrphostin AG490. J. Heart Lung Transpl., 24 (10): 1557-1564, 2005.
123. Shirota, K., Tateishi, K., Emoto, M., Hachisuga, T., Kuroki, Ma. and Kawarabayashi, T.: Relaxin-induced angiogenesis in ovary contributes to follicle development. Ann. New Yok Acad. Sci., 1041: 144-146, 2005.
124. Kuroki, Mo., Yamada, H., Shibaguchi, H., Hachimine, K., Hirose, Y., Kinugasa, T., Ishida, I. and Kuroki, Ma.: Preparation of human IgG and IgM monoclonal antibodies for MK-1/Ep-CAM by using human immunoglobulin gene-transferred mouse and gene cloning of their variable regions. Anticancer Res., 25 (6): 3733-3740, 2005.
125. Kuroki, Ma., Hachimine, K., Huang J., Shibaguchi, H., Kinugasa, T., Maekawa, S. and Kuroki, Mo.: Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity. Anticancer Res., 25 (6): 3725-3732, 2005.
126. Shirota, K., Tateishi, K., Koji, T., Hishikawa, Y., Hachisuga, T., Kuroki, Ma. and Kawarabayashi, T.: Early human preantral follicles have relaxin and relaxin receptor (LGR7), and relaxin promotes their development. J. Clin. Endocrinol. Metab., 90 (1): 516-521, 2005.
127. Ohtsuka, K., Kuroki, Ma., Nojima, T., Waki, M. and Takenaka, S.: Interaction analysis of the carcinoembryonic antigen (CEA) with its monoclonal antibody immobilized on a gold surface using fourier transform infrared reflection-absorption spectroscopy (FT-IR RAS). Anal. Sci., 21 (3): 215-218, 2005.
128. Uno, K., Kuroki, Mo., Hayashi, H., Uchida, H., Kuroki, Ma. and Oshima, K.: Impairment of thrombospondin-1 expression during epithelial wound healing in corneas of vitamin A-deficient mice. Histol. Histopathol., 20 (2): 493-499, 2005.
129. Uchida, H., Hayashi, H., Kuroki, Mo., Uno, K., Yamada, H., Yamashita, Y., Tombran-Tink, J., Kuroki, Ma. and Oshima, K.: Vitamin A up-regulates the expression of thrombospondin-1 and pigment epithelium-derived factor in retinal pigment epithelial cells. Exp. Eye Res., 80 (1): 23-30, 2005.
130. Shibaguchi, H., Kuroki, Ma., Kuroki, Mo., Badran, A., Hachimine, K. and Kinugasa T.: Cloning and sequencing of variable region cDNAs of a novel human monoclonal antibody to carcinoembryonic antigen, and generation of a single chain variable fragmented antibody. Anticancer Res., 24 (5): 3355-3360, 2004.
131. Kuroki, Ma., Kuroki, Mo., Shibaguchi, H., Badran, H., Hachimine, K., Zhang, J. and Kinugasa, T.: Strategies to endow cytotoxic T lymphocytes or natural killer cells with antibody activity against carcinoembryonic antigen. Tumor Biol., 25 (4): 208-216, 2004.
132. Kuroki, Ma., Kuroki, Mo., Shibaguchi, H., Hachimine, K., Kinugasa, T. and Badran, A.: Tumor-targeting of viral vectors for cancer gene therapy by using antibodies or their genes against tumor-associated antigens. Anticancer Res., 24 (5): 3373-3378, 2004.
133. Fujimura, S., Arakawa, F., Yamada, Y., Liao, S., Khare, P.D., Kuroki, Ma. and Ono, J.: Growth arrest and apoptosis in adult T cell leukemia cell lines following IL-2 deprivation. Int. J. Oncol., 25 (2): 437-443, 2004.
134. Uno, K., Hayashi, H., Kuroki, Mo., Uchida, H., Yamauchi, Y., Kuroki, Ma. and Oshima, K.: Thrombospondin-1 accelerates wound healing of corneal epithelia. Biochem. Biophys. Res. Commun., 315 (4): 928-934, 2004.
135. Gyobu, H., Tsuji, T., Suzuki, Y., Ohkuri, T., Chamoto, K., Kuroki, Ma., Miyoshi, H., Kawarada, Y., Katoh, H., Takeshima, T. and Nishimura, T.: Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res., 64 (4): 1490-1495, 2004.
136. Imakiire, T., Kuroki, Mo., Shibaguchi, H., Abe, H., Yamauchi, Y., Ueno, A., Hirose,　Y., Yamada, H., Yamashita, Y., Shirakusa, T., Ishida, I. and Kuroki Ma.: Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen. Int. J. Cancer, 108 (4): 564-570, 2004.
137. Nakayama, J., Tanaka, T., Furumura, M., Takahashi, A., Yamaguchi, T., Shimura, H., Ikeda, S. and Kuroki, Ma.: Inhibition of the proliferation of a malignant peripheral nerve sheath tumor cell line by gamma interferon gene transfection. J. Dermatol., 30 (12): 879-885, 2003.
138. Yamamoto, T., Senba, T., Zhang J., Hirose, Y., Kuroki, Mo. and Kuroki, Ma.: Dialysis-based bioreactor system for the production of chimeric antibodies: an alternative to ascites production in mice. Med. Bull. Fukuoka Univ., 30 (4): 243-247, 2003.
139. Senba, T., Yamamoto, T., Murakami, M., Hachimine, K., Shibaguchi, H. and Kuroki Ma.: Anti-tumor effect of an immunotoxin consisting of a chimeric anti-carcinoembryonic antigen antibody conjugated to ricin toxin A. Med. Bull. Fukuoka Univ., 30 (4): 231-236, 2003.
140. Shibaguchi, H., Arakawa, F., Imakiire, T., Kuroki, Mo. and Kuroki, Ma.: cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody. Anticancer Res., 23 (6): 4383-4388, 2003.
141. Kuroki, Ma., Shibaguchi, H., Imakiire, T., Uno, K., Shirota, K., Higuchi, T., Shitama, T., Yamada, H., Hirose, Y., Nagata, A. and Kuroki, Mo.: Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens. Anticancer Res., 23 (6): 4377-4381, 2003.
142. Kuroki, Ma.: Interview about CEA as a target. Mod. Aspects Immunobiol., 3 (2): 48, 2003.
143. Li, T., Tachibana, K., Kuroki, Mo. and Kuroki, Ma.: Gene transfer with echo-enhanced contrast agents: comparison between albunex, optison, and levovist in mice―initial results. Radiology, 229 (2): 423-428, 2003.
144. Fujimura, S., Suzumiya, J., Yamada, Y., Kuroki, Ma. and Ono, J.: Downregulation of Bcl-xL and activation of caspases during retinoic acid-induced apoptosis in an adult T cell leukemia cell line. Hematol. J., 4 (5): 328-335, 2003.
145. Yamauchi, Y., Kuroki, Mo., Imakiire, T., Uno, K., Yamashita, Y., Shirakusa, T. and Kuroki, Ma.: Thrombospondin-1 inhibits interleukin-10 release from monocytic cells through interaction with CD47. Med. Bull. Fukuoka Univ., 30 (3): 141-147, 2003.
146. Fukushima, K., Ikehara, Y., Kanai, M., Kochibe, N., Kuroki, Ma. and Yamashita, K.: A b-N-acetylglucosaminyl phosphate diester residue is attached to the glycosylphosphatidylinositol anchor of human placental alkaline phosphatase: A target of the channel-forming toxin aerolysin . J. Biol. Chem., 278 (38): 36296-36303, 2003.
147. Nakayama, J., Tanaka, T., Arakawa, F., Terao, H., Shimura, H., Ikeda, S. and Kuroki, Ma.: Gamma interferon gene transfection efficiently inhibits proliferation of neurofibroma cell lines in vitro. J. Dermatol., 30 (3): 181-188, 2003.
148. Kuroki, Ma.: Gene therapy in cancer via use of a retrovector having a tumor specificity and expressing inducible nitric oxide synthase. In: Methods in Molecular Biology, Vol. 279, Nitric Oxide Protocols. (A. Hassid, ed.), Humana Press, Totowa (USA), pp. 201-211, 2003.
149. Arakawa, F., Shibaguchi, H., Xu, Z. and Kuroki, Ma.: Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity. Anticancer Res., 22 (6): 4285-4290, 2002.
150. Kuroki, Ma., Ueno, A., Matsumoto, H., Abe, H., Li, T., Imakiire, T., Yamauchi, Y., Uno, K., Shirota, K., Shibaguchi, H. and Kuroki, Mo.: Significance of tumor-associated antigens in the diagnosis and therapy of cancer: an overview. Anticancer Res. 22 (6): 4255-4264, 2002.
151. Bjerner, J., Lebedin, Y., Bellanger, L., Kuroki, Ma., Shively, J.E., Varaas, T., Nustad, K., Hammarstrom, S. and Bormer, O. P.: Protein epitopes in carcinoembryonic antigen - Report from the ISOBM TD-8 workshop. Tumor Biol., 23 (4): 249-262, 2002.
152. Abe, H., Kuroki, Mo., Imakiire, T., Yamauchi, Y., Yamada, H., Arakawa, F. and Kuroki, Ma.: Preparation of recombinant MK-1/Ep-CAM and establishment of an ELISA system for determining soluble MK-1/Ep-CAM levels in sera of cancer patients. J. Immunol. Methods, 270 (2): 227-233, 2002.
153. Zhao, L., Xu, S., Peterson, C., Kuroki, Mo., Kuroki, Ma. and Venge, P.: Purification and characterization of a 95 kDa protein―Carcinoembryonic antigen-related cell adhesion molecule 8―from normal human granulocytes. J. Immunol. Methods, 270 (1): 27-35, 2002.
154. Khare, P. D., Liao, S., Hirose, Y., Kuroki, Mo., Fujimura, S., Yamauchi, Y., Miyajima-Uchida, H. and Kuroki, Ma.: Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene. Anticancer Res., 22 (4): 2443-2446, 2002.
155. Matsumoto, H., Liao, S., Arakawa, F., Ueno, A., Abe, H., Awasthi, A., Kuroki, Mo. and Kuroki, Ma.: Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody. Anticancer Res., 22 (4): 2001-2007, 2002.
156. Yamauchi, Y., Kuroki, Mo., Imakiire, T., Uno, K., Abe, H., Beppu, R., Yamashita, Y., Kuroki, Ma. and Shirakusa, T.: Opposite effects of thrombospondin-1 via CD36 and CD47 on homotypic aggregation of monocytic cells. Matrix Biol., 21 (5): 441-448, 2002.
157. Abe, H., Kuroki, Mo., Tachibana, K., Li, T., Awasthi, A., Ueno, A., Matsumoto, H., Imakiire, T., Yamauchi, Y., Yamada, H., Ariyoshi, A. and Kuroki, Ma.: Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen. Anticancer Res., 22 (3): 1575-1580, 2002.
158. Satoh, Y., Hayashi, T., Takahashi, T., Itoh, F., Adachi, M., Fukui, M., Kuroki, Mo., Kuroki, Ma., Imai, K. and Hinoda, Y.: Expression of CD66a in multiple myeloma. J. Clin. Lab. Anal., 16 (2): 79-85, 2002.
159. Kinugasa, T., Kuroki, Ma., Takeo, H., Kuroki, Mo., Yamashita, Y. and Shirakusa, T.: Significance of CEACAM6 in the signet ring cell carcinoma of the stomach. Med. Bull. Fukuoka Univ., 29 (2): 95-99, 2002.
160. Ueno, A., Arakawa, F., Matsumoto, H., Imakiire, T., Uno, K., Abe, H., Miyajima-Uchida, H., Yamauchi, Y., Kuroki, Mo. and Kuroki, Ma.: Cloning and sequencing of cDNAs encoding V regions of monoclonal antibody F106-88 specific for CEACAM6 and construction of a mouse/human chimeric antibody. Med. Bull. Fukuoka Univ., 29 (2): 83-93, 2002.
161. Ueno, A., Arakawa, F., Abe, H., Matsumoto, H., Kudo, T., Asano, R., Tsumoto, K., Kumagai, I., Kuroki, Mo. and Kuroki, Ma.: T-cell immunotherapy for human MK-1expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Anticancer Res., 22 (2): 7696-776, 2002.
162. Yamauchi, Y., Kuroki, Mo., Imakiire, T., Abe, H., Uchida, H., Beppu, R., Yamashita, Y., Shirakusa, T. and Kuroki, Ma.: Thrombospondin-1 differentially regulates release of IL-6 and IL-10 by human monocytic cell line U937. Biochem. Biophys. Res. Commun., 290 (5): 1551-1557, 2002.
163. Jirsa, M., Muchova L., Draberova L., Draber, P., Smid, F., Kuroki, Ma., Marecek, Z. and Groen, A. K.: Carcinoembryonic antigen-related cell adhesion molecule 1 is the 85-kDa pronase-resistant biliary glycoprotein in the cholesterol crystallization promoting low density protein-lipid complex. Hepatology, 34 (6): 1075-1082, 2001.
164. Muchova, L., Jirsa, M., Kuroki, Ma., Dudkova, L., Benes, M. J., Marecek, Z. and Smid, F.: Immunoaffinity isolation of CEACAM1 on hydrazide-derivatezed cellulose with immobilized monoclonal anti-CEA antibody. Biomedical Chromatography, 15 (6): 418-422, 2001.
165. Watt, S. M., Teixeira, A. M., Zhou, G. Q., Doyonnas, R., Zhang, Y., Grunert, F., Blumberg, R. S., Kuroki, Mo., Akubitz, K. M. and Bates, P. A.: Homophilic adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the binding site. Blood, 98 (5): 1469-1479, 2001.
166. Kuroki, Mo., Abe, H., Imakiire, T., Liao, S., Uchida, H., Ymauchi, Y., Oikawa, S. and Kuroki, Ma.: Identification and comparison of residues critical for cell adhesion activities of two neutrophil CD66 antigens, CEACAM6 and CEACAM8. J. Leukoc. Biol., 70 (4): 543-550, 2001.
167. Kondo, Y., Hinoda, Y., Akashi, H., Sakamoto, H., Itoh, F., Hirata, K., Kuroki, Ma. and Imai, K.: Measurement of circulating biliary glycoprotein (CD66a) in liver diseases. J. Gastroenterol., 36 (7): 470-475, 2001.
168. Liao, S., Khare, P. D., Arakawa, F., Kuroki, Mo., Hirose, Y., Fujimura, S., Tomita, Y. and Kuroki, Ma.: Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein. Anticancer Res., 21 (3): 1673-1680, 2001.
169. Saga, T., Sakahara, H.., Nakamoto, Y., Sato, N., Ishimori, T., Mamede, M., Kobayashi, H., Masunaga, S., Sasai, K., Kuroki, Ma. and Konishi, J.: Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia. Eur. J. Cancer, 37 (11): 1429-1434, 2001.
170. Beppu, R., Nakamura, K., Miyajima-Uchida, H., Kuroki, Mo., Khare, P. D., Yamauchi,Y., Yamashita, Y., Shirakusa, T. and Kuroki, Ma.: Soluble thrombospondin-1 suppresses T cell proliferation and enhances IL-10 secretion by antigen presenting cells stimulated with phytohemagglutinin. Immunol. Invest., 30 (2): 143-156, 2001.
171. Khare, P. D., Liao, S., Kuroki, Mo., Hirose, Y., Arakawa, F., Nakamura, K., Tomita, Y. and Kuroki, Ma.: Specifically targeted killing carcinoembryonic antigen (CEA)- expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Res., 61 (1): 370-375, 2001.
172. Nishiyama, R., Sakaguchi, T., Kinugasa, T., Gu, X., MacDermott, R. P., Podolsky, D. K. and Reinecker, H. C.: Interleukin-2 receptor beta subunit-dependent and -independent regulation of intestinal epithelial tight junctions. J. Biol. Chem., 276 (38): 35571-35580, 2001.
173. Khare, P. D., Liao, S., Kuroki, Mo., Arakawa, F. and Kuroki, Ma.: Specific gene therapy of CEA-expressing tumor cells using reconstructed retrovirus. In: 2nd Congress of the Federation of Immunological Societies of Asia-Oceania (FIMSA) (S. Sirisinha, S. C. Chaiyaroj and P. Tapchaisri, eds.), Monduzzi Editore, Bologna (Italy), PP. 51-55, 2000.
174. Shibaguchi, H., Himeno, A., Shigematsu, K., Kataoka, Y. and Niwa, M.: Transient hypoxia/hypoglycemia upregulate endothelin B receptors in cultured rat astrocytes. Glia, 31 (1): 91-94, 2000.
175. Shibaguchi, H., Takemura, K., Kan, S., Kataoka, Y., Kaibara, M., Saito, N. and Taniyama, K.: Role of synaptophysin in exocytotic release of dopamine from Xenopus oocytes injected with rat brain mRNA. Cell. Mol. Neurobiol., 20 (3): 401-408, 2000.
176. Kuroki, Ma., Arakawa, F., Khare, P. D., Kuroki, Mo., Liao, S., Matsumoto, H., Abe, H. and Imakiire, T.: Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA. Anticancer Res., 20 (6): 4067-4071, 2000.
177. Oikawa, S., Sugiyama, M., Kuroki, Mo., Kuroki, Ma. and Nakazato, H.: Extracellular N-domain alone can mediate specific heterophilic adhesion between members of the carcinoembryonic antigen family, CEACAM6 and CEACAM8. Biochem. Biophys. Res. Commun., 278 (3): 564-568, 2000.
178. Egawa, K., Honda, Y., Kuroki, Ma. and Ono, T.: The carcinoembryonic antigen (CEA) family (CD66) expressed in melanocytic naevi is not expressed in blue naevuscell naevi in dendritic type. J. Cutan. Pathol., 27 (7): 351-358, 2000.
179. Egawa, K., Kuroki, Ma., Inoue, Y., Ono, T.: Nail bed keratinocytes express an antigen of the carcinoembryonic antigen family. Br. J. Dermatol., 143 (1): 79-83, 2000.
180. Sato, N., Saga, T., Sakahara, H., Nakamoto, Y., Zhao, S. J., Kuroki, Ma., Iida, Y., Endo, K. and Konishi, J.: Avidin chase can reduce myelotoxicity associated with radioimmunotherapy of experimental liver micrometastases in mice. Jpn. J. Cancer Res., 91: 622-628, 2000.
181. Tomita, Y., Arakawa, F., Hirose, Y., Liao, S., Khare, P. D., Kuroki, Mo., Yamamto, T., Ariyoshi, A. and Kuroki, Ma.: Carcinoma-associated antigens MK-1 and CEA in urological cancers. Anticancer Res., 20 (2): 793-797, 2000.
182. Watanabe, N., Oriuchi, N., Endo, K., Inoue, T., Kuroki, Ma., Matsuoka, Y., Tanada, S., Murata, H., Kim, E. E. and Sasaki, Y.: CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer. J. Nucl. Med., 41 (2): 337-344, 2000.
183. Miyajima-Uchida, H., Hayashi, H., Beppu, R., Kuroki, Mo., Fukami, M., Arakawa, F., Tomita, Y., Kuroki, Ma. and Oshima, K.: Production and accumulation of thrombospondin-1 in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci., 41 (2): 561-567, 2000.
184. Tomita, Y., Arakawa, F., Yamamoto, T., Kuwahara, M., Watanabe, R., Iwasaki H., Kikuchi, M. and Kuroki, Ma.: Molecular identification of a human carcinoma-associated glycoprotein antigen recognized by mouse monoclonal antibody FU-MK-1. Jpn. J. Cancer Res., 91 (2): 231-238, 2000.
185. Kinugasa, T., Sakaguchi, T., Gu, X. and Reinecker, H. C.: Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology, 118 (6): 1001-1011, 2000.